Universal Vision Biotechnology Co., Ltd.

Total Valuation

Universal Vision Biotechnology Co., Ltd. carries a market capitalization of 12.33B, placing it among publicly traded companies globally. Its enterprise value stands at 11.48B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Universal Vision Biotechnology Co., Ltd. currently has 84.72M shares outstanding.

Valuation Ratios

Universal Vision Biotechnology Co., Ltd. trades at a trailing price-to-earnings ratio of 11.88. The price-to-sales ratio is 2.95, and the price-to-book ratio stands at 3.92.

Enterprise Valuation

On an enterprise value basis, Universal Vision Biotechnology Co., Ltd. trades at an EV/EBITDA multiple of 8.34 and an EV/FCF ratio of 5.10. The EV/Sales ratio of 2.73 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 8.34 provides insight into valuation relative to core operating earnings.

Financial Position

Universal Vision Biotechnology Co., Ltd. maintains a current ratio of 2.92, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 25.57, indicating elevated leverage, while an interest coverage ratio of 55.43 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Universal Vision Biotechnology Co., Ltd. posts a return on equity of 34.71 and a return on invested capital of 20.89.

Taxes

Over the trailing twelve months, Universal Vision Biotechnology Co., Ltd. has paid 290.98M in income taxes, reflecting an effective tax rate of 21.63.

Stock Price Statistics

Universal Vision Biotechnology Co., Ltd.'s stock has declined approximately -28.14815% over the past 52 weeks. The 50-day moving average sits at 133.45, while the 200-day moving average is 141.06.

Income Statement

Over the trailing twelve months, Universal Vision Biotechnology Co., Ltd. generated 4.20B in revenue and converted that into 1.04B in net income, yielding earnings per share of 12.41. EBITDA reached 1.38B, while operating income came in at 1.38B.

Balance Sheet

Universal Vision Biotechnology Co., Ltd. holds 2.10B in cash and equivalents against 1.06B in total debt, resulting in a net debt position of -685.75M. Total book value stands at 3.16B, with working capital of 1.97B providing operational flexibility.

Cash Flow

Universal Vision Biotechnology Co., Ltd. produced 1.67B in operating cash flow over the past twelve months. After subtracting -563.82M in capital expenditures, free cash flow totaled 1.10B - equivalent to 13.00 per share.

Margins

Universal Vision Biotechnology Co., Ltd. operates with a gross margin of 59.05, reflecting its pricing power and cost economics. The operating margin of 32.76 and net profit margin of 24.80 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Universal Vision Biotechnology Co., Ltd.'s most recent stock split took place on August 25, 2023 with a 50:53 split ratio.

Scores

Universal Vision Biotechnology Co., Ltd. posts an Altman Z-Score of 6.20, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.